Today: 21 July 2026
Sadot Shares Surge 78% as Filing Formula Suggests 61 Million Shares in Reserve
20 July 2026
2 mins read

Sadot Shares Surge 78% as Filing Formula Suggests 61 Million Shares in Reserve

NEW YORK, July 20, 2026, 06:14 EDT

  • Sadot finished Friday at $25.30, a 77.5% increase, though it rose just 7.8% over the week.
  • An initial assessment of the note contract results in a registration reserve of 61.3 million shares.
  • The reserve should not be interpreted as an issuance forecast. The purchase price for the initial closing was $3.6 million.

Shares of Sadot Group Inc. surged 77.5% on Friday. Market focus may soon turn to potential dilution, as a filing expected this week could register approximately 61.3 million shares under a note resale.

The amount is about 60 times greater than the 1,022,235 common shares listed as outstanding on July 16. This total represents a registration reserve rather than an estimate of actual shares to be issued.

The calculation is based on the full issuance of $100 million in notes. It incorporates two years of interest at 8.25% and utilizes the existing $2.85 minimum. The agreement subsequently imposes a 150% coverage rate.

The calculation begins with $116.5 million in principal and accrued interest. When divided by $2.85 and increased by 150%, the result is approximately 61.3 million shares.

Based on the current share count, the reserve is almost five times greater than Sadot’s 12.5 million authorized common shares. The agreement stipulates that approval for additional authorized shares and potential reverse stock splits must be obtained within 50 days.

Note conversions are still limited to around 204,000 shares before approval, according to Nasdaq’s 19.99% restriction. The cap is distinct from the registration reserve, which covers separate criteria.

Current-basis comparisonSharesMultiple of July 16 outstanding
Disclosed common shares in circulation1.022 million 1.0x
Limit on note conversion before consentRoughly 204,000 0.20x
Total common shares authorized12.5 million 12.2x
Initial reserve for note registrationRoughly 61.3 million 60.0x

Sadot ended the session at $25.30, with trading volume near 24 million shares. Turnover was around 23 times the company’s reported number of shares outstanding. Despite this, the stock rose just 7.8% for the week after dropping 39.3% by Thursday.

Nasdaq’s regular session had ended by 06:14 EDT on Monday. Sadot was trading near $27 in premarket action. Premarket trading remained open.

The opening note carried a $4 million principal and was bought for $3.6 million, which amounts to 1.8% of the $200 million nominal financing figure. Shares ended Friday trading at a level 42% higher than the original $17.81 conversion price.

The remaining $100 million represents an equity line rather than available cash. Standard buying prices are set at 95% or 98% of market benchmarks defined by the contract. These benchmarks take the lesser value between lowest trades and hourly VWAPs.

Much of the note capacity is still subject to conditions. Company-led tranches are subject to a 30-trading-day waiting period, which begins once both the registration is effective and the last closing has taken place. Additional requirements include maintaining a $10 VWAP and a daily turnover of $2 million. These conditions may be waived by the buyer.

The filing also detailed Sadot’s acquisition of TradeIQ software for $6 million. The deal involved 200,000 common shares worth $2 million, along with the issuance of $3.95 million in preferred stock and a commitment to pay $50,000 in cash.

The common shares had a value of $5.06 million at the close on Friday. The consideration securities are subject to a 180-day lock-up period.

According to a preliminary and unreviewed estimate from management, adjusted shareholders’ equity exceeds $7 million. Nasdaq requires a minimum of $2.5 million. The filing offered no guarantee that the exchange will approve.

The next key event is the registration statement required by the contract, expected on Sunday, July 26. Investors are focused on its share count and any indications toward achieving shareholder approval.

Risks: Registration does not guarantee issuance, and a significant portion of funding might not be completed. On the other hand, decreased conversion prices, equity-line transactions, and approvals from shareholders could heighten dilution. The notes are backed by nearly all assets.

Friday saw a single session with high trading volumes. The contracts depend on ongoing liquidity, official approvals and valid registrations prior to the release of the majority of funds.

Michał Rogucki is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic developments. A graduate of Humboldt University of Berlin, he previously worked in investment research and market analysis before transitioning to financial journalism. He covers the trends and events that matter most to investors worldwide.

Stock Market Today

  • Cadiz, ArriVent BioPharma, Acco Brands join Zacks Strong Sell list for July 21st
    July 21, 2026, 6:12 AM EDT. Cadiz (CDZI), ArriVent BioPharma (AVBP), and Acco Brands (ACCO) were added to the Zacks Rank #5 (Strong Sell) List. Cadiz's earnings estimate tumbled 40%, while ArriVent BioPharma slipped 7.3% and Acco Brands dropped 5.1% in consensus earnings over the past 60 days. These moves mark a significant slide in expected earnings for July 21st.
American Airlines (NASDAQ:AAL) under pressure as margins in focus following 12% weekly drop
Previous Story

American Airlines (NASDAQ:AAL) under pressure as margins in focus following 12% weekly drop

Nvidia (NASDAQ:NVDA) stock trades steady despite broader chip sector losses
Next Story

Nvidia (NASDAQ:NVDA) stock trades steady despite broader chip sector losses

Go toTop